Scientific Programme
Monday 12 December

  • Monday 12 December 2016
  • 08:00
    Interactive computerized radiology workshop
  • Session 1: Follow-up
    08:15 - 09:30 hrs.
    • 08:15
      Symptoms and quality of life of colorectal cancer survivors: Results of the population-based PROFILES registry

      Lonneke van de Poll-Franse, Netherlands Cancer Institute, Amsterdam, the Netherlands
    • 08:40
      Follow-up after curative surgery for colorectal cancer

      Peer Wille-Jørgensen, Bispebjerg & Frederiksberg Hospital, Copenhagen, Denmark
    • 09:05
      CEA Watch trial

      Charlotte Verberne, Medical Centrum Twente, Enschede, the Netherlands
  • Session 2: Health economics and quality of care
    09:30 - 10:45 hrs.
    • 09:30
      Variations in patterns of CRC care – which lessons can be learned?

      Dr. Richard Adams, University Hospital of Wales, United Kingdom
    • 09:55
      The impact of digital decision support tools on quality of colorectal care

      Martijn van Oijen, Academic Medical Center, the Netherlands
    • 10:20
      Long term surgical morbidity and reintervention after rectal cancer treatment; a snapshot population based analysis

      Pieter Tanis, Academic Medical Center, the Netherlands
  • 10:45
  • Session 3: Updated results from phase 3 trials
    11:15 - 12:30 hrs.
    • 11:15
      The FACS trial: the role of CT and CEA in colorectal cancer follow up

      John Primrose, Univesity of Southampton, United Kingdom
    • 11:30
      CREST trial (stent as bridge to surgery versus acute resection)

      James Hill, Manchester Royal Infirmary, United Kingdom
    • 11:45
      The German CAO/ARO/AIO-04 study

      Claus Rodel, University of Frankfurt, Germany
    • 12:00
      Translational research CAIRO3 study

      Miriam Koopman, University Medical Center Utrecht, the Netherlands
    • 12:15
      New EPOC trial

      John Primrose, University of Southampton, United Kingdom
  • Oral presentations selected abstracts
    12:30 - 13:00 hrs.
    • 12:30
      Randomised phase 3 study of S-1 versus capecitabine (+/- bevacizumab) in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group

      Drs. Kwakman, Academic Medical Center, Amsterdam, the Netherlands
    • 12:40
      Novel Histopathological Prognostic Markers In Microsatellite Unstable Colorectal Cancer

      Dr. E. Ryan, St. Vincents University Hospital, Dublin, Ireland
    • 12:50
      Trifluridine/tipiracil versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial

      Marc Peeters, Antwerp University Hospital, Belgium
  • 13:00
    Lunch & Posters
  • 14:00
    Key-note lecture: The genomic landscape of colorectal cancer

    Federica Di Nicolantonio, University of Turin, Italy
  • Session 4: Translational research
    14:45 - 15:15 hrs.
    • 14:45
      Radiomics: there is more than meets the eye

      Philippe lambin, MAASTRO clinic, the Netherlands
    • 15:00
      The mesenchymal nature of aggressive colon cancer as a lead to develop subtype-targeted therapy

      Onno Kranenburg, University Medical Center Utrecht, the Netherlands
  • Session 5: Controversy 1
    15:15 - 16:00 hrs.
    • 15:15
      PRO || Oxaliplatin has a role in the (neo)adjuvant treatment of locally advanced rectal cancer

      Dirk Arnold, CUF Cancer Center, Portugal
    • 15:30
      CON || Oxaliplatin has a role in the (neo)adjuvant treatment of locally advanced rectal cancer

      David Sebag-Montefiore, University of Leeds, United Kingdom
    • 15:45
  • 16:00
  • Session 6: Multidisciplinary management 1
    16:30 - 17:50 hrs.
    • 16:30
      Whole body imaging for detection of distant metastases: what’s new?

      Vincent Vandecaveye, University Hospitals Leuven, Belgium
    • 16:50
      Treatment of screen detected early colon and rectal cancers

      Roel Hompes, University of Oxford, United Kingdom
    • 17:10
      Anti-VEGF versus anti-EGFR antibodies in RAS wildtype metastatic CRC: what are the data?

      Axel Grothey, Mayo Clinic, United States
    • 17:30
      Role of SIRT in the management of CRC liver metastases

      Thomas Helmberger, Institute for Diagnostic and Interventional Radiology München, Germany
  • 18:00
    Drinks & Posters